Dr. Anita Hill, a hematologist with extensive expertise in the management of PNH and aHUS/TTP using eculizumab shares with us an outstanding lecture on Primary Thrombotic Microangiopathies and the Role of Complement.

Complement dysregulation is an important process in the pathophysiology of atypical HUS/TTP. Targeting this important mechanistic step with eculizumab - a novel antibody against a terminal complement protein - might have an important role in the management of this rare and challenging clinical problem.

Launch Lecture
Click the image above to begin

ukidneyisup